Respiratory Syncytial Virus

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Interventions targeting respiratory viruses should be considered as a means of protecting against invasive pneumococcal disease in children, study finds.

The FDA set a Prescription Drug User Fee Act for May 2023 for Pfizer’s respiratory syncytial virus bivalent vaccine candidate.

Phase 3 trial results indicate efficacy against respiratory syncytial virus-lower respiratory tract disease in individuals aged 60 years and older.

The COVID-19 and flu test is a single-use at-home test kit that uses self-collected nasal swab samples and provides results in approximately 30 minutes.

If approved, the vaccine would be the first immunization for use in pregnant individuals to help protect against the complications of respiratory syncytial virus in infants from birth through 6 months.

One of the major concerns about getting a flu vaccine is its safety for women during pregnancy.

Despite the large number of prescription products available, nondrug therapies often work just as well.

Pharmacists play a vital role in educating patients about differentiating among the common cold, COVID-19, influenza, and respiratory syncytial virus.

Single nasal swab test can determine whether a patient has COVID-19, influenza, respiratory syncytial virus, or a combination of these viruses in as little as 2 hours.

The mRNA-1345 vaccine candidate was previously granted Fast Track designation by the FDA in August 2021.

Respiratory syntactical virus burdens quality of life and can lead to long-term health outcomes.

Based on study findings, Moderna plans to submit for regulatory approval in the first half of 2023 for mRNA-1345, a novel vaccine for respiratory syncytial virus.

Research showed that 600 hospital beds filled with patients with severe illness would be enough to reimplement (mask mandates to stop the spread of infection.

The impact of RSV includes serious financial challenges, strained relationships, and mental health concerns.

Counseling sessions offer opportunity to educate about appropriate dosing, potential adverse effects.

There are currently 33 RSV prevention candidates in clinical development using 6 different approaches.

Pharmacists should educate patients about managing respiratory syncytial virus and let them know they may soon be able to get vaccinated.

The updated recommendations during a surge in cases emphasize the need to enhance emergency readiness daily to not interrupt continuous care of children’s mental and physical well-being.

When mildly ill, individuals who reflect on the potential consequences of their behavior are less likely to go to holiday gatherings and events.

Respiratory syncytial virus- and rhinovirus-induced wheezing illnesses differ from each other at multiple levels.

Palivizumab is a humanized monoclonal antibody approved by the FDA to prevent serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children.

RSVpreF produced vaccine efficacy of 66.7% against respiratory syncytial virus-associated lower respiratory tract illness in older adults.

Interventions such as mask-wearing and social distancing have been found effective at limiting the spread of respiratory diseases.

Investigators find that despite the same quantity of respiratory syncytial virus and presentation, some of the samples demonstrated signs of greater damage to cells.

A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.

American Society of Consultant Pharmacists executive director and CEO explained how staffing struggles in long-term care facilities can be an opportunity for pharmacists to expand the ways they provide support beyond immunizations alone.

Infection with RSV can take a variety of forms, ranging from a mild upper respiratory tract infection to severe, life-threatening acute respiratory failure.

Pre-planned safety reviews performed for the duration of the study found that the investigational vaccine is well-tolerated with no safety concerns for both the vaccinated individuals and their newborns.

Researchers suggest that winter 2020 to 2021 public health interventions lowered natural immunity in children and put them at greater risk of respiratory infection after restrictions were lifted.